Table 2.
Reactions of clinically defined sera with HCoV nucleocapsids
| Serum no. | 229E-N | NL63-N | OC43-N | HKU1-N | SARS-N | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCoV-OC43a | BCM-1A | BCM-1B | ++ | ++ | ++ | ++ | − | +++ | − | +++ | − | − |
| BCM-2A | BCM-2B | − | − | + | + | − | +++ | − | ++ | − | − | |
| BCM-3A | BCM-3B | + | + | − | − | + | + | − | − | − | − | |
| BCM-4A | BCM-4B | − | − | + | + | + | +++ | − | +++ | − | − | |
| BCM-5A | BCM-5B | ++ | +++ | ++ | +++ | + | +++ | + | +++ | − | − | |
| BCM-6A | BCM-6B | ++ | ++ | +++ | ++ | + | ++ | + | ++ | − | − | |
| HCoV-229Eb | BCM-7A | BCM-7B | ++ | ++ | ++ | ++ | ++ | ++ | ++ | + | − | − |
| BCM-8A | BCM-8B | ++ | ++ | ++ | ++ | + | + | + | − | − | − | |
| BCM-9A | BCM-9B | − | +++ | ++ | +++ | + | + | − | − | − | − | |
| BCM-10A | BCM-10B | + | + | + | + | − | ++ | − | + | − | − | |
| BCM-11A | BCM-11B | ++ | +++ | ++ | ++ | +++ | +++ | ++ | +++ | − | − | |
| BCM-12A | BCM-12B | + | ++ | ++ | ++ | ++ | ++ | ++ | ++ | − | − | |
a
BCM-1 to BCM-6: serum samples of HCoV-OC43–infected patients.
b
BCM-7 to BCM-12: serum samples of HCoV-229E–infected patients; A: acute phase; B: convalescent phase; positive reactions are indicated with + (moderate), ++ (strong), and +++ (very strong); negative/no reactions are indicated with −.